 Cathie Wood-led Ark Investment Management has bought 628,060 shares of clinical-stage biopharmaceutical company Fate Therapeutics Inc. NASDAQ: FATE through two of the firms exchange-traded funds ETF valued at over 20 million based on Thursdays closing pri 